Medication info
Olmesartan Plus Tablet 20/12.5 mg

Olmesartan Plus Tablet 20/12.5 mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Yellowish round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201100985 · Approved 2011.02.25 · Insurance code 665001490

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Before administering this drug, it is recommended that the dosage of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with either component alone, administer 1 tablet of this drug once daily, with or without food. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is added or patients are switched to this drug (olmesartan medoxomil/hydrochlorothiazide) in patients taking high-dose hydrochlorothiazide monotherapy and in patients with volume depletion or hyponatremia. In such cases, reduce the hydrochlorothiazide dose to 12.5mg before adding olmesartan medoxomil. <Elderly patients> In elderly patients, start with the lowest dose and use caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal failure> This drug (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal failure (creatinine clearance>30mL/min). Do not administer this drug (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal failure, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic failure> Use of this drug is not recommended in patients with hepatic failure because there is no experience with its use in these patients.
Child dose
Safety and efficacy have not been established in children.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Olmesartan Medoxomil and Hydrochlorothiazide are medications used for the treatment of essential hypertension. If blood pressure control is insufficient with monotherapy, these medications can be combined to effectively lower blood pressure. These drugs help relax blood vessels and promote sodium and fluid excretion, aiding in blood pressure control. Managing hypertension is crucial for preventing cardiovascular disease, so consistent use and regular blood pressure monitoring are necessary. This combination therapy contributes to improving patients' blood pressure and reducing the risk of complications.

How to take

Adult dose

Before administering this drug, it is recommended that the dosage of olmesartan medoxomil or hydrochlorothiazide be adjusted separately. If blood pressure is not adequately controlled with either component alone, administer 1 tablet of this drug once daily, with or without food. Adjust the dose at intervals of 2~4 weeks, taking the patient's blood pressure response into consideration. A marked reduction in blood pressure may occur when olmesartan medoxomil is added or patients are switched to this drug (olmesartan medoxomil/hydrochlorothiazide) in patients taking high-dose hydrochlorothiazide monotherapy and in patients with volume depletion or hyponatremia. In such cases, reduce the hydrochlorothiazide dose to 12.5mg before adding olmesartan medoxomil. <Elderly patients> In elderly patients, start with the lowest dose and use caution when adjusting the dose, taking into consideration the patient's renal or cardiac function, comorbidities, and other concomitant medications. <Patients with renal failure> This drug (olmesartan medoxomil/hydrochlorothiazide) is generally administered to patients with mild to moderate renal failure (creatinine clearance>30mL/min). Do not administer this drug (olmesartan medoxomil/hydrochlorothiazide) to patients with more severe renal failure, as loop diuretics are preferable to thiazide diuretics in these patients. <Patients with hepatic failure> Use of this drug is not recommended in patients with hepatic failure because there is no experience with its use in these patients.

Child dose

Safety and efficacy have not been established in children.

Precautions

This medication can cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be administered to patients with known allergies to the components of this drug, those with certain kidney and liver diseases, pregnant or breastfeeding women, and patients with certain genetic metabolic disorders. Patients with low blood volume or sodium should be monitored closely when starting treatment as hypotension may occur initially. Use with caution in patients with impaired renal function, kidney transplant recipients, those with specific heart diseases, liver dysfunction, elderly individuals, and infants; regular blood tests to monitor renal function and electrolyte status should be performed if necessary. This medication can cause electrolyte imbalances, so if symptoms such as dry mouth, muscle cramps, or dizziness occur, medical consultation should be sought immediately. Blood pressure may drop significantly during treatment, so it is advisable to avoid high-altitude work or operating dangerous machinery. This medication may interact with various drugs; therefore, patients taking other medications must inform their healthcare provider, particularly when using potassium supplements, other antihypertensives, diuretics, lithium, or non-steroidal anti-inflammatory drugs. If breastfeeding, it is advisable to either stop breastfeeding or discontinue this medication as it may pass into breast milk and affect the infant. Safety and efficacy in pediatric patients have not yet been established, hence it is advisable not to use it in children. In case of overdose, symptoms such as hypotension, electrolyte imbalances, and dehydration may occur; appropriate treatment should be sought immediately. Rarely, side effects such as skin rash, headache, dizziness, gastrointestinal disturbances, blood abnormalities may occur; if symptoms persist or worsen, consult a healthcare provider.

Side effects

Nausea, hyperuricemia, dizziness, upper respiratory infection, headache, urinary tract infection, chest pain, low back pain, peripheral edema, lightheadedness, abdominal pain, dyspepsia, gastroenteritis, diarrhea, AST elevation, GGT elevation, ALT elevation, hyperlipidemia, creatine phosphokinase elevation, hyperglycemia, cough, rash, hematuria, facial edema, weakness, angioedema, anaphylactic reaction, vomiting, rhabdomyolysis, acute renal failure, increased serum creatinine, hair loss, pruritus, urticaria, hyponatremia, polyuria, palpitations, hypertension, epistaxis, asthma, chronic malabsorption syndrome, intestinal vascular edema, palpitations, orthostatic hypotension, arrhythmia, transient blurred vision, jaundice, choroidal exudate, jaundice, hepatitis, acute cholecystitis, necrotizing vasculitis, interstitial pneumonia, pulmonary edema, dyspnea, interstitial pneumonia, acute respiratory distress syndrome, malaise, nasal congestion, erectile dysfunction, systemic lupus erythematosus exacerbation, hypercalcemia, muscle cramps, sensory disturbance, weakness, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis, toxic epidermal necrolysis, hypokalemia, hypomagnesemia, hypochloremic alkalosis, anorexia, polydipsia, abdominal discomfort, constipation, abdominal colic, pancreatitis, sialadenitis, dry mouth, dizziness, fatigue, drowsiness, emotional blunting, restlessness, headache, thrombocytopenia, leukopenia, aplastic anemia, hemolytic anemia, purpura, abnormal liver function tests, increased serum creatinine, increased serum BUN, increased serum creatinine, increased serum potassium, decreased serum sodium, decreased serum magnesium

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture. The storage temperature should be suitable in a cool place between 1 and 25 degrees. This helps maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Yellowish round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.